PATHFINDER was one of the first studies to try the Galleri® test in ordinary clinic settings rather than a lab. Across more than 6,600 people aged 50 and over, it showed the test could be slotted into routine care. When a signal was found, its prediction of where the cancer was helped doctors investigate quickly — and most cancers it detected had no other routine screening available
Source: sciencedirect.com
The NHS-Galleri trial followed over 140,000 people. Its main goal wasn't met — but the most advanced, stage IV diagnoses fell
PATHFINDER 2 followed nearly 36,000 adults over 50 across the US and Canada — the largest look yet at how well the test performs.
A follow-up asked how people coped emotionally with cancer blood testing. Most reported little distress, and those who got a signal returned to normal within a year.